The Improvement of General Condition and Immunity Function of CKD After Treatment With Bailing Capsule: A Randomized Clinical Trial

Background: The management of chronic kidney disease (CKD) presents significant challenges, with people often exploring new treatment strategies and medications in an attempt to slow disease progression. This study seeks to evaluate the efficacy of Bailing capsules in the treatment of CKD. Methods: A total of 148 patients with CKD and renal and spleen qi insufficiency were included in this study. The experimental group ( n = 87) received Bailing capsules in addition to the standard treatment, while the control group ( n = 61) received only the standard treatment. The study used both subjective and objective endpoints, including traditional Chinese medicine (TCM) syndrome scores, routine blood tests, biochemical markers, and lymphocyte counts, to evaluate the efficacy of Bailing capsules. Results: After statistical analysis, we found that the experimental group showed a significant decrease in TCM syndrome scores and in various biochemical indices, including reduced levels of cystatin C, 24‐h urine protein, bilirubin, gamma‐glutamyl transferase, and urinary red blood cell count ( p < 0.05). Additionally, the experimental group demonstrated an increase in white blood cell counts and regulation of immune function markers, such as CD3, CD4, and CD19 ( p < 0.05). Conclusion: After treatment, the relevant indicators of CKD showed significant improvement, and the patients’ immune function was also partially regulated. Notably, no significant adverse reactions were observed that would necessitate the termination of the study. Further investigation is required to gain a deeper understanding of these findings, particularly regarding the effects of Bailing capsules on immune function regulation in CKD. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR‐IPR‐17014157